Neurocrine Biosciences (NBIX) Cash from Operations Growth (1y) (2011 - 2026)
Powered by 
Analysis
Neurocrine Biosciences (NBIX) Cash from Operations Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | 122.18% |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | -33.32% |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | 63.07% |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | -11.73% |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 243.47% |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | 107.90% |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | - |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 1,034.67% |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | 63.59% |
| 10 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | 33.73% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 33.73% |
| Mar 31, 2026 | 125.00% |
| Dec 31, 2025 | 60.16% |
| Sep 30, 2025 | 43.99% |
| Jun 30, 2025 | 57.89% |
| Mar 31, 2025 | -50.27% |
| Dec 31, 2024 | 96.36% |
| Sep 30, 2024 | -25.47% |
| Jun 30, 2024 | -64.03% |
| Mar 31, 2024 | 204.07% |
| Dec 31, 2023 | -13.64% |
| Sep 30, 2023 | 114.57% |
| Jun 30, 2023 | 30.05% |
| Mar 31, 2023 | -209.14% |
| Dec 31, 2022 | 3,304.76% |
| Sep 30, 2022 | 59.87% |
| Jun 30, 2022 | 33.82% |
| Mar 31, 2022 | -146.39% |
| Dec 31, 2021 | -95.56% |
| Sep 30, 2021 | 402.94% |